Allergen desensitization reduces the severity of relapsed alopecia areata in dust‐mite allergic patients

Abstract

AbstractAtopy may be a facilitating factor in some alopecia areata (AA) patients with early disease onset and more severe/extensive AA. The underlying immune mechanisms are unknown, but allergen responses may support a pro‐inflammatory environment that indirectly promotes AA. To investigate the long‐term effect of allergen immunotherapy (AIT) against house dust mite (HDM) allergy on disease severity and prognosis for AA patients. An observational comparative effectiveness study was conducted on 69 AA patients with HDM allergy. 34 patients received conventional/traditional AA treatment (TrAA) plus AIT (AIT‐TrAA), and 35 patients received TrAA alone. Serum total immunoglobulin E (tIgE), HDM specific IgE (sIgE), HDM specific IgG4 (sIgG4) and cytokines (IL‐4, IL‐5, IL‐10, IL‐12, IL‐13, IL‐33, IFNγ) were quantified in these patients, together with 58 non‐allergic AA patients and 40 healthy controls. At the end of the 3‐year desensitization course, the AIT‐TrAA group presented with lower SALT scores than the TrAA group, especially in non‐alopecia totalis/universalis (AT/U) patients and pre‐adolescent AT/U patients (age ≤ 14). In patients with elevated tIgE levels before AIT, a decrease in tIgE was correlated to reduced extent of AA on completion of the AIT course. After desensitization, elevation of IL‐5 and decrease of IL‐33 were observed in HDM allergic‐AA patients. Desensitization to HDM in allergic AA patients reduces the severity of relapse‐related hair loss over the 3‐year AIT treatment course, possibly via opposing Th2 dominance. This adjunctive treatment may help reduce disease severity and curtail the disease process in allergic patients with AA.